JP5087640B2 - Ｐｌｋ１阻害剤として有用な置換ピリミドジアゼピン - Google Patents

Ｐｌｋ１阻害剤として有用な置換ピリミドジアゼピン Download PDF

Info

Publication number
JP5087640B2
JP5087640B2 JP2009553997A JP2009553997A JP5087640B2 JP 5087640 B2 JP5087640 B2 JP 5087640B2 JP 2009553997 A JP2009553997 A JP 2009553997A JP 2009553997 A JP2009553997 A JP 2009553997A JP 5087640 B2 JP5087640 B2 JP 5087640B2
Authority
JP
Japan
Prior art keywords
mole
methyl
tetrahydro
pyrimido
rac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009553997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010521514A5 (OSRAM
JP2010521514A (ja
Inventor
カイ，ジアンピン
チェン，シャオチン
チュー，シン−ジェ
レ，カン
トーマス ルク，キン−チュン
マイケル ウォブクリッチ，ピーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39415299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5087640(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2010521514A publication Critical patent/JP2010521514A/ja
Publication of JP2010521514A5 publication Critical patent/JP2010521514A5/ja
Application granted granted Critical
Publication of JP5087640B2 publication Critical patent/JP5087640B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2009553997A 2007-03-22 2008-03-11 Ｐｌｋ１阻害剤として有用な置換ピリミドジアゼピン Expired - Fee Related JP5087640B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91935807P 2007-03-22 2007-03-22
US60/919,358 2007-03-22
PCT/EP2008/052847 WO2008113711A1 (en) 2007-03-22 2008-03-11 Substituted pyrimidodiazepines useful as plk1 inhibitors

Publications (3)

Publication Number Publication Date
JP2010521514A JP2010521514A (ja) 2010-06-24
JP2010521514A5 JP2010521514A5 (OSRAM) 2011-04-21
JP5087640B2 true JP5087640B2 (ja) 2012-12-05

Family

ID=39415299

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009553997A Expired - Fee Related JP5087640B2 (ja) 2007-03-22 2008-03-11 Ｐｌｋ１阻害剤として有用な置換ピリミドジアゼピン

Country Status (23)

Country Link
US (1) US7517873B2 (OSRAM)
EP (1) EP2139892B1 (OSRAM)
JP (1) JP5087640B2 (OSRAM)
KR (1) KR101157848B1 (OSRAM)
CN (2) CN101636399B (OSRAM)
AR (1) AR065794A1 (OSRAM)
AT (1) ATE524472T1 (OSRAM)
AU (1) AU2008228303B2 (OSRAM)
BR (1) BRPI0809088A2 (OSRAM)
CA (1) CA2680757A1 (OSRAM)
CL (1) CL2008000785A1 (OSRAM)
CY (1) CY1112102T1 (OSRAM)
DK (1) DK2139892T3 (OSRAM)
ES (1) ES2371832T3 (OSRAM)
HR (1) HRP20110807T1 (OSRAM)
IL (1) IL200617A (OSRAM)
MX (1) MX2009010034A (OSRAM)
PE (1) PE20120495A1 (OSRAM)
PL (1) PL2139892T3 (OSRAM)
PT (1) PT2139892E (OSRAM)
SI (1) SI2139892T1 (OSRAM)
TW (1) TWI363629B (OSRAM)
WO (1) WO2008113711A1 (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2695753A1 (en) * 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinases inhibitors
MX2010003249A (es) * 2007-09-25 2010-11-09 Takeda Pharmaceutical Inhibidores de quinasas símil polo.
CN101878216B (zh) 2007-09-28 2013-07-10 西克拉塞尔有限公司 作为蛋白激酶抑制剂的嘧啶衍生物
WO2009067547A1 (en) * 2007-11-19 2009-05-28 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
WO2009153197A1 (en) * 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Halo-substituted pyrimidodiazepines as plkl inhibitors
NZ593110A (en) 2008-12-09 2013-06-28 Gilead Sciences Inc pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
EP2379559B1 (en) 2009-01-06 2017-10-25 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
AU2010262905B2 (en) 2009-06-17 2015-04-16 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
CA2772253C (en) 2009-09-14 2018-02-27 Gilead Sciences, Inc. Modulators of toll-like receptors
KR20140014110A (ko) 2010-12-16 2014-02-05 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
US9676792B2 (en) * 2013-03-15 2017-06-13 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
KR20160034379A (ko) 2013-07-25 2016-03-29 다나-파버 캔서 인스티튜트 인크. 전사 인자의 억제제 및 그의 용도
TWI652014B (zh) * 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
EP3068782B1 (en) 2013-11-13 2018-05-23 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
ES2741444T3 (es) 2013-11-13 2020-02-11 Vertex Pharma Inhibidores de la replicación de virus de la gripe
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
US10150756B2 (en) 2014-01-31 2018-12-11 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
EA201790024A1 (ru) 2014-07-11 2017-07-31 Джилид Сайэнс, Инк. Модуляторы toll-подобных рецепторов для лечения вич
RU2017104897A (ru) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Производные диазепана и их применения
JP6373490B2 (ja) 2014-09-16 2018-08-15 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体モジュレーターを調製する方法
US9738646B2 (en) 2014-09-16 2017-08-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
KR20180051576A (ko) 2015-09-11 2018-05-16 다나-파버 캔서 인스티튜트 인크. 아세트아미드 티에노트리아졸로디아제핀 및 그의 용도
CN108472300A (zh) 2015-09-11 2018-08-31 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
PE20181298A1 (es) 2015-11-25 2018-08-07 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
CN109311901A (zh) * 2016-04-07 2019-02-05 达纳-法伯癌症研究所有限公司 嘧啶并-二氮杂卓酮激酶骨架化合物及治疗pi3k介导的病变的方法
AU2020356484A1 (en) * 2019-09-27 2022-03-17 Dana-Farber Cancer Institute, Inc. ERK5 degraders as therapeutics in cancer and inflammatory diseases
KR20210122163A (ko) * 2020-03-27 2021-10-08 (주) 업테라 Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물
WO2022145989A1 (ko) * 2020-12-31 2022-07-07 (주) 업테라 선택적 plk1 억제제로서의 피리미도디아제핀 유도체
WO2023017442A1 (en) * 2021-08-10 2023-02-16 Uppthera, Inc. Novel plk1 degradation inducing compound
GB202313514D0 (en) 2023-09-05 2023-10-18 Cambridge Entpr Ltd Treatment of inflammatory diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK3792002A3 (en) 1999-09-17 2003-09-11 Abbott Gmbh & Co Kg Kinase inhibitors as therapeutic agents
HRP20040213A2 (en) * 2001-09-04 2005-02-28 Boehringer Ingelheim Pharma Gmbh & Co.Kg Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
DE602007008837D1 (de) * 2006-02-14 2010-10-14 Vertex Pharma Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
ES2371832T3 (es) 2012-01-10
CN102746175B (zh) 2014-01-15
DK2139892T3 (da) 2011-12-12
US7517873B2 (en) 2009-04-14
HK1139936A1 (en) 2010-09-30
KR101157848B1 (ko) 2012-07-11
HRP20110807T1 (hr) 2011-12-31
TW200843781A (en) 2008-11-16
ATE524472T1 (de) 2011-09-15
IL200617A0 (en) 2010-05-17
MX2009010034A (es) 2009-10-12
PL2139892T3 (pl) 2012-03-30
EP2139892B1 (en) 2011-09-14
PT2139892E (pt) 2011-11-21
JP2010521514A (ja) 2010-06-24
AU2008228303B2 (en) 2012-04-19
CL2008000785A1 (es) 2009-03-27
SI2139892T1 (sl) 2011-12-30
EP2139892A1 (en) 2010-01-06
CA2680757A1 (en) 2008-09-25
PE20120495A1 (es) 2012-05-12
KR20090119913A (ko) 2009-11-20
TWI363629B (en) 2012-05-11
CY1112102T1 (el) 2015-11-04
CN101636399A (zh) 2010-01-27
CN102746175A (zh) 2012-10-24
US20080234255A1 (en) 2008-09-25
AR065794A1 (es) 2009-07-01
BRPI0809088A2 (pt) 2014-09-09
AU2008228303A1 (en) 2008-09-25
CN101636399B (zh) 2012-04-18
WO2008113711A1 (en) 2008-09-25
IL200617A (en) 2014-02-27

Similar Documents

Publication Publication Date Title
JP5087640B2 (ja) Ｐｌｋ１阻害剤として有用な置換ピリミドジアゼピン
TW202128691A (zh) Ｋｒａｓ 突變蛋白抑制劑
CN104854101B (zh) Alk激酶抑制剂
CN111278815A (zh) 戊二酰亚胺
BR122021004509B1 (pt) Sais de inibidor de pi3k e processos para seu preparo
CN107580602A (zh) 5’‑取代的核苷类似物
JP6785876B2 (ja) ピリド［３，４−ｄ］ピリミジン誘導体及びその薬学的に許容される塩
EP3768272B1 (en) Jak inhibitors
KR20220006104A (ko) 유비퀴틴화 특이적 프로테아제 억제제 및 이의 제조 방법과 응용
US11034696B2 (en) Compounds for inhibiting LRRK2 kinase activity
WO2019011228A1 (zh) 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
CN116157400B (zh) 杂环类衍生物及其制备方法和用途
KR102874188B1 (ko) 융합된 아자 헤테로 시클릭 아미드계 화합물 및 이의 용도
WO2020238776A1 (zh) 取代的稠合双环类衍生物、其制备方法及其在医药上的应用
CN110891951A (zh) 化合物
CN114981270B (zh) Mll1抑制剂和抗癌剂
JP2021534122A (ja) 脱ユビキチン化酵素ｕｓｐ２５及びｕｓｐ２８の阻害
JP7369968B2 (ja) 抗がん剤
CN119192203A (zh) 含氮杂环化合物作为泛素-特异性蛋白酶1抑制剂的制备方法、应用及其用途
WO2025237361A1 (zh) 一种氧代三并环类衍生物及其在医药上的应用
EP4539832A2 (en) Phenyl amide compounds and methods of use
WO2024218235A1 (en) Pyrrolopyrazine compounds, preparation thereof and therapeutic uses thereof
JP2024540004A (ja) キナゾリン誘導体化合物およびその用途
CN117624166A (zh) 一种三氮唑衍生物及其制备方法和用途
BR112017018312B1 (pt) Sais de inibidor de pi3k, composições que as compreende, seu uso, processos para seu preparo e método de inibição de uma atividade de uma quinase pi3k

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20100712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120803

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120828

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120910

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150914

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees